An official website of the United States government.

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Delivery of Peanut Allergen Powder Into Epidermis For Safe Immunotherapy

Investigators
Wu, Mei X.
Institutions
Massachusetts General Hospital
Start date
2018
End date
2019
Objective
Project Summary / AbstractThe objective of this proposal is to develop an effective and safe epicutaneous immunotherapy (EPIT) forpeanut allergy. Among various allergen-specific immunotherapies, EPIT is the safest but least effectivetherapy. It is extremely challenging to deliver allergens into the epidermis via intact skin, despite that thenon-vascularized tissue imposes little anaphylactic risk. To enhance epidermic delivery of allergens withoutprovoking any significant skin irritation, we used ablative fractional laser to generate an array of self-renewable microchannels in the epidermis, onto which an antigen powder-based microarray patch wasapplied resulting in ~80% delivery efficiency in ~1 hr via both human and pig skins, concurrent with little skinirritation. We also identified that a combination of CpG and 1,25-dihydroxyvitamin D3 (VD3) could robustlyaugment TGF-β and IL-10 production at the site of allergen delivery and vigorously enhance T regulatory(Treg) cell responses systemically. Only 3 doses of EPIT over two weeks sufficiently inhibited allergen-specific IgE responses in mice, which was unattainable by 8 times of conventional subcutaneousimmunotherapy (SCIT) over three weeks. To further tailor this technology for clinical uses, we propose todeliver powdered allergens directly by Powder-Laden, Dissolvable MicroNeedle Arrays (PLD-MNAs), whichno longer needs laser to perforate the skin. The MNA will be made of highly biocompatible and dissolvablehyaluronic acid (HA) with a cave in the basal portion of each MN. The cave will be about 25~30 µm in depth,similar to the depth of mouse epidermis and can be filled with allergen powder directly. The MNA will bedissolved in 15~20 min after skin insertion, exposing the powder in the epidermis that continuously andactively attracts antigen presenting cells (APCs). We will fabricate PLD-MNAs by loading a mixture of CpG,VD3, and peanut allergens (PNA) into caved MNAs. The resultant PLD-MNAs will be applied into the skin ofsensitized C3H/HeJ mice, followed by evaluation of delivery efficiency, skin irritation, innate immunity, anyPNA leakage into blood as well as humoral and Th1/Treg cell responses against PNA. Skin irritation and anytrace amount of PNA leaking into blood will be also assessed in sensitized newborn pigs to confirm safety ofthe therapy. Aim 2 will seek in a murine peanut allergy model whether 3 doses of the PLD-MNAs are superiorto conventional 8 doses of conventional SCIT in treatment of peanut allergy. The PLD-MNA, if successful,would confer safer and faster treatments of peanut allergy and can be readily extended to other IgE-mediatedallergies.
Funding Source
Nat'l. Inst. of Allergy and Infectious Diseases
Project source
View this project
Project number
1R21AI135233-01
Categories
Salmonella
Antimicrobial Resistance